Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | USP1 | O94782 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639199 | 0.83 | PNMT (0.36) | NR3C2CYP2D6HRH1 | |
| SCHEMBL19346224 | 0.83 | TRPM8 (0.36) | NR3C2TRPM8 | |
| SCHEMBL25744955 | 0.77 | HTR2A (0.33) | NR3C2 | |
| SCHEMBL19132988 | 0.76 | CYP2D6 (0.32) | CYP2D6CHRM1HRH1KCNH2 | |
| SCHEMBL19227962 | 0.75 | NR3C2 (0.56) | NR3C2 | |
| SCHEMBL12120626 | 0.73 | GABRA1 (0.40) | NR3C2 | |
| SCHEMBL20694181 | 0.73 | NR3C2 (0.42) | NR3C2CYP2D6KCNH2L3MBTL1 | |
| SCHEMBL9963324 | 0.73 | CYP2D6 (0.40) | CYP2D6CHRM1HRH1KCNH2L3MBTL1 | |
| SCHEMBL19492754 | 0.72 | CYP2D6 (0.33) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL22040174 | 0.72 | CYP2D6 (0.39) | CYP2D6CHRM1HRH1KCNH2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292349-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292349-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | CX3CR1, CXCR3, CXCR1 | NR3C2 1421/4885CYP2D6 1197/4885CHRM1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.